Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has represented Adelis
Mandate

Vinge has represented Adelis

November 12, 2018 M&A

Vinge has represented Adelis in connection with Presto Brandsäkerhet and Aptum joining forces to become the leading player in fire safety in the Nordic region with revenue of more than SEK 700 million.

In connection with the transaction, Adelis Equity Partners will become the new majority owner. The transaction is subject to customary conditions precedent.

Vinge’s team comprised of, among others, Christina Kokko, Johanna Wiberg, Michaela Cronemyr, Marith Welin-Beger and Fredric Reissmüller (M&A) as well as Johan Wahlbom (competition law) 


 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025